Oncaspar Injection Price in India | 9310090915

1. Buy Oncaspar (Pegaspargase) Injection Oncaspar: Indication and Usage Oncaspar is a cancer medication used to treat acute lymphoblastic leukemia (ALL), a cancer of white blood cells known as lymphoblasts, in adults and children. Oncaspar is prescribed in conjunction with other cancer medications. •Acute Lymphoblastic Leukaemia (ALL)- Oncaspar is suggested as part of a multiagent chemotherapeutic routine for the first-line treatment of ALL patients. •Acute Lymphoblastic Leukaemia and Asparaginase Hypersensitivity Oncaspar is used as part of a multiagent chemotherapy regimen to treat individuals with ALL who are allergic to native versions of L'Asparaginase. This efficient drug is widely available and may be obtained from any respectable vendor. In addition, the Oncaspar injection price in India is affordable. •Oncaspar: Dosage Oncaspar dosage strength includes Pegaspargase 3750 IU per 5 mL solution in a single-use vial. No more than 2,500 International Units/m2 intramuscularly or intravenously • Coagulopathy is possible. Carry out proper monitoring. More than once every 14 days. When administering intramuscularly, limit the volume at a single injection site to 2 mL; if the volume is larger than 2 mL, utilize multiple injection sites. •Oncaspar: Administration While administering Oncaspar intramuscularly, one should limit the volume at a single injection site to 2 mL. Multiple injection sites should be used if the volume to be delivered is larger than 2 mL. Only use one dose per vial; discard any unused product. Oncaspar should be given intravenously over 1-2 hours in 100 mL of sodium chloride or dextrose injection 5% via an already

2. running infusion. The solution should be used immediately after being diluted for intravenous usage. If immediate usage is not possible, keep the diluted solution refrigerated at 2°C to 8°C (36°F to 46°F). Keep infusion bags out of direct sunlight. Through Indian Pharma Network, you can buy Oncaspar injectionat an affordable price. The Indian Pharma Network facilitates access to new products in India. •Oncaspar: Contradiction Even though oncaspar injections are readily available in the market under valid prescription, there are specific contradictions associated with the drug that needs to be checked before using the drug. • A history of severe allergic responses to Oncaspar • Initial approval in the United States: 1994, history of L- asparaginase therapy for significant thrombosis • History of L-asparaginase therapy for pancreatitis • History of L-asparaginase therapy resulted in significant hemorrhagic episodes. •Oncaspar: Warnings and Precautions If any of the following occur, one should stop using Pegaspargase injection- •Anaphylaxis or other severe allergic responses- Observe patients for 1 hour after receiving Oncaspar in a place equipped with resuscitation equipment and additional anaphylactic-treatment drugs (for example, epinephrine, oxygen, intravenous steroids, and

3. antihistamines). In patients who have severe allergic reactions, discontinue Oncaspar. oThrombosis- Patients on Oncaspar may experience serious thrombotic events, including sagittal sinus thrombosis. In patients who have had major thrombotic events, discontinue Oncaspar. •Pancreatitis- Examine people who have abdominal pain for signs of pancreatitis. In individuals with pancreatitis, discontinue Oncaspar. •Glucose intolerance, which might be permanent in some cases, can ensue. •Oncaspar: Adverse effects Signs of liver problems, reduced blood clotting, high levels of fats in the blood, high levels of blood glucose, and low levels of white blood cells followed by fever are the most common side effects of Oncaspar (which may affect more than one in ten people). Oncaspar should not be used in patients with severe liver illness, pancreatitis (including pancreatitis caused by past asparaginase treatments), or significant bleeding or substantial blood clots after asparaginase treatment. •Oncaspar: Mechanism of Action Oncaspar's mechanism of action is assumed to be based on the selective death of leukemic cells caused by plasma asparagine depletion. Due to a lack of asparagine synthetase, some leukemic cells cannot synthesize asparagine and must rely on an exogenous source of asparagine to survive. Asparagine depletion, caused by therapy with the enzyme L- asparaginase, destroys the leukemic cells. On the other hand, normal cells are less impacted by the deficiency since they can synthesize asparagine.

4. This powerful pharmaceutical is on the market and may be obtained from any respectable vendor. Furthermore, the Oncaspar price in India is inexpensive. •Oncaspar: Description Oncaspar (pegaspargase) is a covalently conjugated L- asparaginase (L-asparagine amidohydrolase) to monomethoxypolyethylene glycol (mPEG). L-asparaginase is a tetrameric enzyme generated by E. coli that consists of identical 34.5 kDa subunits. Oncaspar is a clear, colorless, preservative-free isotonic sterile solution in phosphate-buffered saline with a pH of 7.3. In water for injection, USP, each milliliter includes 750 150 International Units of pegaspargase, dibasic sodium phosphate, monobasic sodium phosphate, and sodium chloride. You can easily purchase this drug at effective rates as Pegaspargase injection cost in India, and it is economical through Indian Pharma Network. •Oncaspar: Use in Specific Population oPregnancy - Pregnancy Type C. Oncaspar has not been subjected to animal reproduction studies. It is also unknown whether Oncaspar can induce foetal damage or alter reproductive ability when provided to a pregnant woman. Oncaspar should only be given to a pregnant woman if necessary. oBreastfeeding Mothers Oncaspar is not known to be excreted in human milk. Oncaspar has the potential for severe adverse reactions in nursing infants, a choice should be made to terminate breastfeeding or discontinue the drug, taking the importance of the treatment to the mother into account. •Oncaspar: Overdosage Three patients received an intravenous infusion of 10,000 International Units/m2 of Oncaspar. Liver enzyme levels in one patient slightly rose. A second patient experienced a rash 10

5. minutes after the infusion began, which was managed by administering an antihistamine and slowing down the infusion rate. A third patient did not have any negative responses. To know more about the drug or its overdose and Pegaspargase price in India, you can refer to the Indian Pharma Network, which connects patients with legitimate pharmaceutical suppliers, wholesalers, and dealers. Source -https://helpforheallth.blogspot.com/2023/06/oncaspar- pegaspargase-injection-for.html